Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Infinitopes has a double victory at the 15th Annual OBN Awards 2023

The OBN Awards recognise companies that demonstrate outstanding leadership, innovative practices, and significant contributions towards addressing clinical needs at different stages of development.

Celebrating 5 years of the Oxford BioEscalator

The BioEscalator recently marked its 5th anniversary with a celebration that showcased the impressive journeys of some of its current and graduated biotech companies.

Hutano Diagnostics acquired by EDX Medical Group

We are delighted that BioEscalator resident start-up Hutano Diagnostics has announced its acquisition by Cambridge, UK-based EDX Medical Group PLC.

Inspiring stories shared at The Africa Oxford Health Innovation platform programme

The BioEscalator community engaged with the talented cohort of innovators from The Africa Oxford Health Innovation Platform (AfOx-HIP) programme, a collaborative initiative by the University of Oxford fostering innovation and entrepreneurship to address crucial health challenges in Africa.

Infinitopes announced as OBN Awards 2023 finalist in two categories

We are pleased to announce that Infinitopes has been named as a finalist in two categories for the upcoming OBN Awards 2023. The company's consistent excellence earned it recognition in the Best Start-up Biotech category for the second year while being selected as a finalist for the esteemed BioSeed 'One to Watch' category.

BioEscalator Pitch Battle 2023

Pitching a business idea to potential investors is nerve-wracking for any entrepreneur. The pressure to effectively convey a company's vision, potential, and market viability can be overwhelming. However, for the innovative companies associated with the BioEscalator, this task became an opportunity to shine at the fourth annual BioEscalator Pitch Battle.

BioEscalator presented with LEAF Bronze Award at the Vice Chancellor’s Environmental Sustainability Awards 2023

The BioEscalator, alongside resident company Alethiomics, was presented with the award, showing commitment towards sustainable practices.

Connecting startups to cutting-edge laboratory facilities in Oxford

The BioEscalator and Oxford University Innovation teamed up to hold an event to showcase the state-of-the-art laboratory facilities at the University of Oxford to resident BioEscalator companies and start-ups from the Oxfordshire innovation ecosystem.

Oxford Cancer Analytics raises $3.7M led by Eka Ventures to revolutionise liquid biopsy and early cancer detection

The Oxford and Toronto-based company will invest in expanding its first-in-class international studies and developing products for the deadliest cancers that can benefit most from liquid biopsy early detection.

Oxford Cancer Analytics part of Oxford team that aims to detect lung cancer early via a simple blood test

The team from Oxford University Hospitals (OUH) NHS Foundation Trust, the Oxford Radcliffe Biobank and the local spin-out company Oxford Cancer Analytics (OXcan) will recruit 200 participants to identify cancer biomarkers - molecules such as proteins found in blood that are a sign of lung cancer.

Alethiomics and Infinitopes shortlisted in the New Startup of the Year category for the Cancer Research Horizons Innovation & Entrepreneurship Awards 2022

Alethiomics is uncovering new biology to discover and develop life-changing treatments for patients with blood cancer, and Infinitopes is identifying hidden tumour targets, enabling the creation of high-efficiency vaccines.

Ochre Bio outgrows the BioEscalator

With Ochre Bio's chemistry laboratory housed at The Oxford Science Park, it was a no-brainer for the company to move over to the park when it outgrew the BioEscalator.

Nucleome Therapeutics raises oversubscribed £37.5M Series A financing

Nucleome Therapeutics, a recently graduated BioEscalator tenant, has closed an oversubscribed £37.5M Series A financing round. The funds will be used to advance the biotech company's autoimmune disease programmes, fuel the expansion of its dark genome atlas and further develop its pioneering platform.

Mental health in the SME community

Starting up your own business is challenging at the best of times; business plans, funding, licensing and IP are just a few of the hurdles founders face. In addition to the global pandemic and the current financial crisis in the UK, SMEs are under more pressure than ever.

Ochre Bio raises $30M (£27M) Series A financing for the development of RNA therapies for chronic liver diseases

Ochre Bio's Series A funding will support the development of its first candidates for IND-enabling studies and expand discovery and RNA chemistry capabilities to address a wider set of serious liver-related diseases.

The BioEscalator bids farewell to Nucleome Therapeutics

Nucleome Therapeutics has outgrown its space at the BioEscalator and moved to pastures new. The company will continue its growth journey at The Oxford Science Park.

Load More